{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:37Z","timestamp":1791983677869,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014978","name":"BSR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The last British Society for Rheumatology (BSR) guideline on PMR was published in 2009. The guideline needs to be updated to provide a summary of the current evidence for pharmacological and non-pharmacological management of adults with PMR. This guideline is aimed at healthcare professionals in the UK who directly care for people with PMR, including general practitioners, rheumatologists, nurses, physiotherapists, occupational therapists, pharmacists, psychologists and other health professionals. It will also be relevant to people living with PMR and organisations that support them in the public and third sector, including charities and informal patient support groups. This guideline will be developed using the methods and processes outlined in the BSR Guidelines Protocol. Here we provide a brief summary of the scope of the guideline update in development.<\/jats:p>","DOI":"10.1093\/rap\/rkae002","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T20:53:37Z","timestamp":1708116817000},"source":"Crossref","is-referenced-by-count":9,"title":["Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-9281","authenticated-orcid":false,"given":"Task","family":"Toyoda","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Armitstead","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leeds Teaching Hospitals NHS Trust , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampada","family":"Bhide","sequence":"additional","affiliation":[{"name":"East Elmbridge Primary Care Network, Kingston Hospital NHS Foundation Trust , Kingston upon Thames, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Engamba","sequence":"additional","affiliation":[{"name":"Norwich Practices Health Centre , Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Stockport NHS Foundation Trust , Stockport, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jones","sequence":"additional","affiliation":[{"name":"Powys Teaching Health Board, Bronllys Hospital , Brecon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"MacKeith","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Maddock","sequence":"additional","affiliation":[{"name":"Patient Expert, PMRGCAuk , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-8708","authenticated-orcid":false,"given":"Gary","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Centre for Immunology and Inflammatory Diseases, Massachusetts General Hospital , Boston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scrafton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Northumbria Healthcare NHS Foundation Trust , Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5688-0153","authenticated-orcid":false,"given":"Manil","family":"Subesinghe","sequence":"additional","affiliation":[{"name":"King\u2019s College London and Guy\u2019s and St Thomas\u2019 PET Centre , London, UK"},{"name":"Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Subesinghe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-1268","authenticated-orcid":false,"given":"Helen","family":"Twohig","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2483-5873","authenticated-orcid":false,"given":"Sarah L","family":"Mackie","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Yates","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich, UK"},{"name":"Rheumatology Department, Norfolk and Norwich University Hospitals NHS Foundation Trust , Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"2024021620532735900_rkae002-B1","author":"British Society for Rheumatology","year":"2022"},{"key":"2024021620532735900_rkae002-B2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2024021620532735900_rkae002-B3","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-016-1097-8","article-title":"Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study","volume":"18","author":"Muller","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024021620532735900_rkae002-B5","author":"Kay","year":"2021"},{"key":"2024021620532735900_rkae002-B6","author":"National Health Service","year":"2019"},{"key":"2024021620532735900_rkae002-B7","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024021620532735900_rkae002-B8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","article-title":"The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population","volume":"17","author":"Yates","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2024021620532735900_rkae002-B10","doi-asserted-by":"crossref","first-page":"e0126758","DOI":"10.1371\/journal.pone.0126758","article-title":"\u201cAn impediment to living life\u201d: why and how should we measure stiffness in polymyalgia rheumatica?","volume":"10","author":"Mackie","year":"2015","journal-title":"PLoS One"},{"key":"2024021620532735900_rkae002-B11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.39514.653588.80","article-title":"Polymyalgia rheumatica","volume":"336","author":"Michet","year":"2008","journal-title":"BMJ"},{"key":"2024021620532735900_rkae002-B12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","article-title":"Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study","volume":"41","author":"Salvarani","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2024021620532735900_rkae002-B13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/annrheumdis-2018-214386","article-title":"Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study","volume":"78","author":"Yates","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2005.046912","article-title":"Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990\u20132001","volume":"65","author":"Smeeth","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B15","doi-asserted-by":"crossref","first-page":"152017","DOI":"10.1016\/j.semarthrit.2022.152017","article-title":"Subclinical giant cell arteritis in new onset polymyalgia rheumatica: a systematic review and meta-analysis of individual patient data","volume":"55","author":"Hemmig","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024021620532735900_rkae002-B16","doi-asserted-by":"crossref","first-page":"e000100","DOI":"10.1136\/rmdopen-2015-000100","article-title":"Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review","volume":"1","author":"Mackie","year":"2015","journal-title":"RMD Open"},{"key":"2024021620532735900_rkae002-B17","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s00259-020-05162-6","article-title":"Diagnostic value of [18F]FDG-PET\/CT in polymyalgia rheumatica: a systematic review and meta-analysis","volume":"48","author":"van der Geest","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024021620532735900_rkae002-B18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","article-title":"Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study","volume":"39","author":"Mazzantini","year":"2012","journal-title":"J Rheumatol"},{"key":"2024021620532735900_rkae002-B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024021620532735900_rkae002-B20","doi-asserted-by":"crossref","first-page":"rkac034","DOI":"10.1093\/rap\/rkac034","article-title":"Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study","volume":"6","author":"Muller","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2024021620532735900_rkae002-B21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"2024021620532735900_rkae002-B23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"2024021620532735900_rkae002-B24","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2024021620532735900_rkae002-B25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00296-021-05036-6","article-title":"What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study","volume":"42","author":"Weddell","year":"2022","journal-title":"Rheumatol Int"},{"key":"2024021620532735900_rkae002-B26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/rheumatology\/kez664","article-title":"British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary","volume":"59","author":"Mackie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024021620532735900_rkae002-B27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/1\/rkae002\/56666768\/rkae002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/1\/rkae002\/56666768\/rkae002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T20:53:59Z","timestamp":1708116839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae002\/7606885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae002","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,12,9]]},"article-number":"rkae002"}}